Sangiovanni Timothy J. 4

What Happened

• Timothy J. Sangiovanni, SVP Finance & Corporate Controller of Zevra Therapeutics (ZVRA), sold 3,000 shares on February 3, 2026. The Form 4 reports a weighted-average sale price of $9.18 per share for total proceeds of $27,548. The filing lists the transaction as an open-market or private sale (code S).

Key Details

• Transaction date: 2026-02-03; Form 4 filed: 2026-02-04 (filed the next day).
• Price: weighted average $9.18; actual trade prices ranged $8.93–$9.52 (see footnote).
• Shares disposed: 3,000; total reported proceeds: $27,548.
• Shares owned after transaction: not disclosed in the provided summary.
• Footnotes: F1 — transaction executed under a 10b5-1 trading plan adopted 3/28/2025; F2 — multiple trades produced the weighted-average price and the reporter can provide per-trade details on request.
• Filing timeliness: appears timely (filed one day after the reported transaction).

Context

• This was a sale, which is often routine (and in this case was executed under a prearranged 10b5-1 plan). A 10b5-1 plan allows insiders to sell according to a predetermined schedule and does not, by itself, indicate current management sentiment. The filing is factual—no inference about motivations should be drawn.